EA202091984A1 - Направленная дзетакинами т-клеточная иммунотерапия, нацеленная на рецептор il-13 альфа 2 - Google Patents
Направленная дзетакинами т-клеточная иммунотерапия, нацеленная на рецептор il-13 альфа 2Info
- Publication number
- EA202091984A1 EA202091984A1 EA202091984A EA202091984A EA202091984A1 EA 202091984 A1 EA202091984 A1 EA 202091984A1 EA 202091984 A EA202091984 A EA 202091984A EA 202091984 A EA202091984 A EA 202091984A EA 202091984 A1 EA202091984 A1 EA 202091984A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- receptor
- alpha
- directed
- receptors
- zetakin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
- C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
- C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
- C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
- C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Некоторые варианты осуществления способов и композиций, предложенных в настоящем документе, включают клетки, имеющие прикрепленные к мембране направленные мутеином IL-13 дзетакиновые рецепторы, такие как рецепторы, которые специфически связываются с рецептором IL-13 альфа 2 (IL13Ra2) с аффинностью, в 50 раз превышающей аффинность IL-13 дикого типа, и способы клеточной иммунотерапии, нацеленной на раковые клетки, такие как клетки солидных опухолей, с применением этих композиций. В некоторых вариантах осуществления рецепторы включают спейсерные области, такие как определенные спейсерные области, предназначенные для обеспечения определенных преимуществ.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862643139P | 2018-03-14 | 2018-03-14 | |
PCT/US2019/021833 WO2019178085A1 (en) | 2018-03-14 | 2019-03-12 | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202091984A1 true EA202091984A1 (ru) | 2021-02-18 |
Family
ID=67907266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202091984A EA202091984A1 (ru) | 2018-03-14 | 2019-03-12 | Направленная дзетакинами т-клеточная иммунотерапия, нацеленная на рецептор il-13 альфа 2 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210017246A1 (ru) |
EP (1) | EP3765487A4 (ru) |
JP (2) | JP7314161B2 (ru) |
KR (1) | KR20200131851A (ru) |
CN (1) | CN112088165A (ru) |
AU (2) | AU2019234580B2 (ru) |
BR (1) | BR112020018534A2 (ru) |
CA (1) | CA3093791A1 (ru) |
EA (1) | EA202091984A1 (ru) |
IL (1) | IL277268A (ru) |
MX (1) | MX2020009464A (ru) |
SG (1) | SG11202008926RA (ru) |
WO (1) | WO2019178085A1 (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024041650A1 (en) * | 2022-08-25 | 2024-02-29 | Nanjing Legend Biotech Co., Ltd. | Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090257994A1 (en) * | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
ES2961498T3 (es) * | 2008-08-26 | 2024-03-12 | Hope City | Método y composiciones para el funcionamiento mejorado del efecto antitumoral de las células T |
JP5956342B2 (ja) | 2009-11-03 | 2016-07-27 | シティ・オブ・ホープCity of Hope | 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt) |
DK2997134T3 (da) | 2013-05-14 | 2020-09-28 | Univ Texas | Human anvendelse af genmanipulerede kimære antigenreceptor-(car)-t-celler |
WO2016044811A1 (en) | 2014-09-19 | 2016-03-24 | City Of Hope | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Rα2 |
JP6905163B2 (ja) * | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | サイトカイン放出症候群を予測するバイオマーカー |
CA3013773A1 (en) * | 2016-02-05 | 2017-08-10 | City Of Hope | Administration of engineered t cells for treatment of cancers in the central nervous system |
AU2017301880C1 (en) * | 2016-07-29 | 2022-04-21 | Juno Therapeutics, Inc. | Immunomodulatory polypeptides and related compositions and methods |
AU2017319702A1 (en) | 2016-09-02 | 2019-04-11 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
-
2019
- 2019-03-12 BR BR112020018534-5A patent/BR112020018534A2/pt unknown
- 2019-03-12 MX MX2020009464A patent/MX2020009464A/es unknown
- 2019-03-12 EP EP19767433.6A patent/EP3765487A4/en active Pending
- 2019-03-12 WO PCT/US2019/021833 patent/WO2019178085A1/en unknown
- 2019-03-12 SG SG11202008926RA patent/SG11202008926RA/en unknown
- 2019-03-12 EA EA202091984A patent/EA202091984A1/ru unknown
- 2019-03-12 JP JP2020549002A patent/JP7314161B2/ja active Active
- 2019-03-12 AU AU2019234580A patent/AU2019234580B2/en active Active
- 2019-03-12 US US16/979,475 patent/US20210017246A1/en active Pending
- 2019-03-12 KR KR1020207028968A patent/KR20200131851A/ko unknown
- 2019-03-12 CN CN201980030021.9A patent/CN112088165A/zh active Pending
- 2019-03-12 CA CA3093791A patent/CA3093791A1/en active Pending
-
2020
- 2020-09-10 IL IL277268A patent/IL277268A/en unknown
-
2023
- 2023-07-12 JP JP2023114641A patent/JP2023134631A/ja active Pending
-
2024
- 2024-04-24 AU AU2024202681A patent/AU2024202681A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11202008926RA (en) | 2020-10-29 |
EP3765487A4 (en) | 2022-01-05 |
JP2021518111A (ja) | 2021-08-02 |
EP3765487A1 (en) | 2021-01-20 |
IL277268A (en) | 2020-10-29 |
US20210017246A1 (en) | 2021-01-21 |
CA3093791A1 (en) | 2019-09-19 |
MX2020009464A (es) | 2021-01-15 |
AU2019234580B2 (en) | 2024-02-01 |
CN112088165A (zh) | 2020-12-15 |
JP2023134631A (ja) | 2023-09-27 |
AU2019234580A1 (en) | 2020-10-08 |
WO2019178085A1 (en) | 2019-09-19 |
AU2024202681A1 (en) | 2024-05-16 |
JP7314161B2 (ja) | 2023-07-25 |
BR112020018534A2 (pt) | 2020-12-29 |
KR20200131851A (ko) | 2020-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39313A1 (fr) | Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers | |
PH12018502601A1 (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
CR20200571A (es) | Moléculas de únion contra bcma y usos de las mismas | |
CL2018000458A1 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso | |
CR20210084A (es) | Receptores quiméricos y métodos de uso de los mismos (divisional 2018-0480) | |
EA201600190A1 (ru) | Анти-prlr антитела и их применение | |
CR20200539A (es) | Receptores quiméricos de dll3 y métodos para su uso | |
MX2020010241A (es) | Composiciones de inmunoterapia celular y usos de las mismas. | |
EA202091982A1 (ru) | Химерный антигенный рецептор к рецептору il-13 альфа 2 (il13r2) для опухолеспецифической т-клеточной иммунотерапии | |
EA201900561A1 (ru) | Конъюгаты циклодекстрин-белок-лекарственное средство | |
EA201790175A1 (ru) | Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований | |
MX353476B (es) | Anticuerpos anti-cxcl13 y metodos para usarlos. | |
EA201070695A1 (ru) | Молекулы гуманизированных антител, специфичных к il-31 | |
WO2021007428A3 (en) | Molecules, compositions and methods for treatment of cancer | |
MX2018015277A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
CR20210197A (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g | |
PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
EA200702361A1 (ru) | АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ | |
EA202091887A1 (ru) | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры | |
MX2019012360A (es) | Composiciones y metodos mejorados de celulas t. | |
BR112022025295A2 (pt) | Células natural killer modificadas geneticamente para imunoterapia do câncer direcionada a cd70 | |
MA33276B1 (fr) | Anticorps spécifiques à la cadhérine-17 | |
EA201290759A1 (ru) | Антитела | |
EA201892440A1 (ru) | Антитела к tl1a и их применения | |
CR20210091A (es) | Receptores químericos de steap1 y métodos de uso de los mismos antecedentes de la invención |